Wedbush Reiterates Buy Rating on ZURA, Sets $15 Price Target
Wedbush remains bullish on ZURA, maintaining its buy rating with a price target of $15, a 172.73% upside from the current price.
Key Points
- Wedbush reiterated its buy rating on ZURA with a $15 price target on July 1, 2026.
- Wedbush's $15 price target implies 172.73% upside from Zura Bio Limited's ($ZURA) current $5.50 share price.
- ZURA shares traded near $5.50 on Wednesday with insider buying activity noted on June 17, 2026.
- Suvrettra Capital and Venrock Adviser increased their ZURA holdings significantly in recent filings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On July 1, 2026, Wedbush reaffirmed its buy rating on ZURA, setting a price target of $15. Analyst Martin Fan from Wedbush believes in the stock's potential, maintaining a bullish stance without altering the target price.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in ZURA
Suvrettra Capital Management, LLC increased its holdings in ZURA by 3.5 million shares, resulting in a total of about 9.1 million shares valued at approximately $53.9 million, a 62.9% increase. Venrock Adviser, LLC also boosted its stake by 1,089,875 shares, holding about 6.4 million shares worth $38.3 million, marking a 20.4% increase. Meanwhile, JPMorgan Chase & Co slightly trimmed its position by 13,905 shares, maintaining around 4.5 million shares valued at $25.3 million. Great Point Partners LLC added 400,000 shares, bringing its total to 4.2 million shares worth $25.1 million, reflecting a 10.5% increase. Siren, L.L.C. notably grew its position by 2,434,866 shares, totaling about 3.7 million shares valued at $22.2 million, a significant 187.3% increase.
Zura Bio Limited Stock Down 3.8%
Shares of ZURA traded near $5.50 on Wednesday. Despite the recent analyst activity, the stock has shown varied movements, with institutional investors making notable changes to their portfolios. The stock's performance continues to attract attention from both analysts and investors.
$ZURA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Zura Bio Limited
On June 17, 2026, several insiders including Steven Schoch, Mark Eisner, Daniel Becker, Jennifer Jarrett, Amit Munshi, and Parvinder Thiara each bought 51,000 shares of ZURA. These transactions were not part of any pre-planned trading programs, indicating a strong belief in the company's future prospects.
Analysts Set New Price Targets
On July 1, 2026, Wedbush reiterated its buy rating on ZURA with a $15 price target. Earlier, on March 23, 2026, Chardan Capital maintained its buy rating with an $11 target, and on March 20, 2026, Oppenheimer also kept a buy rating with a $15 target. The consensus among analysts remains positive, with most maintaining a buy recommendation.
Bottom Line
Wedbush's reaffirmation of a buy rating on ZURA with a $15 target highlights continued confidence in the company's potential. The stock's recent trading activity and insider buying suggest that both institutional and individual investors are keeping a close eye on ZURA's performance. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect current market conditions.
Get Zura Bio Limited alerts
New 13F filings, insider trades, and analyst moves on $ZURA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.